Is Myocardial Stunning Induced by Continuous Renal Replacement Therapy a Reality in Critically Ill Patients?

Myocardial stunning during chronic intermittent hemodialysis is a well-described phenomenon. Little case series of patients presenting myocardial stunning during renal replacement therapy for acute kidney injury in critically ill patients are reported, with intermittent hemodialysis and continuous renal replacement therapy. However, the small sample sizes and the absence of a control arm limit their interpretation, mainly whether the myocardial stunning may be related to cardiac loading conditions variations and whether it may impact the hemodynamic.

The investigator hypothesize that myocardial stunning induced by renal replacement therapy is frequent, independent from cardiac loading conditions and associated with peripheral hypoperfusion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Kidney Injury KDIGO 3 Acute Kidney Injury Cardiovascular Diseases Continuous Renal Replacement Therapy Initiated by the Clinician in Charge Without Emergency Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Heart Diseases Kidney Diseases Male Urogenital Diseases Myocardial Stunning Pathological Conditions, Signs and Symptoms Renal Insufficiency Signs and Symptoms Urogenital Diseases Urologic Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ruste Martin, Bron, BRON, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age > 18 years old
Acute Kidney Injury grade 3 (KDIGO)
Indication for renal replacement therapy for the clinician in charge

Exclusion criteria

Emergency indication to renal replacement therapy (pH<7.15, Kaliemia > 6mmol/L, refractory pulmonary oedema)
Poor echogenicity with speckle tracking analysis failure
Chronic hemodialysis
Extra corporeal membrane oxygenation, left ventricular assist device.

Treatment and study plan

Continuous Renal Replacement Therapy

Procedure

Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter

Control Group

Other

Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations

Primary outcomes

Number of segment of the left ventricle with regional wall motion abnormalities

Time frame: Change between the echocardiography at baseline and the echocardiography 4 hours after.

Numbers of segments of the left ventricle (by patient) with a decrease greater than 20% of the peak systolic longitudinal strain (2D speckle tracking) on the second echocardiography as compared to baseline.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: MS-CRRT

Important dates

Study start: 2022
Primary completion: 2025
Study completion: 2025
First posted: Jan 26, 2022
Registry last updated: Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed